

High-Cost Drugs

Financial and Operational Impacts of High-Cost Cell and Gene Therapies (CGT)

August 8, 2024 David McMahon, CPA, Principal, Memphis Janine Statt, Pharm.D., Principal, Phoenix

A business of Marsh McLennan

welcome to brighter

This presentation is created on behalf of Mercer Health & Benefits, LLC (Mercer) for services in support of training offered by HSFO. This material is for educational purposes only and does not contain any consulting advice. The information contained herein is current as of the date of presentation and is provided by Mercer **"as is"**. Mercer expressly disclaims responsibility, liability, or both for any reliance on this presentation by any third parties or the consequences of any unauthorized use or disclosure other than as mutually contemplated when we were first retained by HSFO to provide this information.

Mercer Agenda

- 1. Reimbursement and treatment cost complexities arising from recently approved high-cost Cell and Gene Therapies (CGT) that must be administered in an inpatient setting
- 2. Key considerations when estimating the potential fiscal impact of new and upcoming Cell and Gene Therapies
- 3. Risk mitigation options for all high-cost drugs in a managed care environment

David McMahon, CPA

Principal, Senior Government Consultant, Policy and Operations

David assists Mercer's Medicaid clients with the management of financial operations

Janine Statt, Pharm.D.

Principal, Senior Medical Consultant, Pharmacy

Janine assists Mercer's Medicaid clients with the management of pharmacy benefits

Learning Objectives

At the conclusion of this presentation, participants will be able to:

Identify payment complexities due to inpatient administration of cell and gene therapies



List risk mitigation options for high-cost drugs within managed care







Describe state-specific factors needed to estimate fiscal impact of high-cost cell and gene therapies




Cell and Gene Therapy: Inpatient Complexities



Inpatient Cell and Gene Therapy: Reimbursement Variables



Inpatient Cell and Gene Therapy: Cost Variables



2 Cell and Gene Therapy:

Cell and Gene Therapy: Planning for the Unknown



Current Landscape of High-Cost Drugs

- The FDA has approved 37 Cell and Gene Therapies as of April 2024
- A robust pipeline of new therapies will contribute to accelerated growth
- Currently eligible populations will continue to increase with expanded indications on the horizon
- Interaction with managed care necessitates discussion on how costs should be built into capitation rates


Select List of Approved Gene and Cell Therapy Products

Drug	Condition	Approval Date	Total US Prevalence; Potentially Eligible Subset	Restrictions	One-Time Drug Cost	
Zolgensma®	Spinal Muscular Atrophy (SMA)	May 2019	1 in 10,000 births	Age less than 2	\$2.125 million	
Zynteglo®	Transfusion-Dependent β-Thalassemia (TDT)	August 2022	1,000 prevalence	Ages 4 and older	\$3.1 million	
Hemgenix® and Beqvez™	Hemophilia B	November 2022 and April 2024	6,070 prevalence; 1,440 eligible	Ages 18 and older; no inhibitors	\$3.5 million	
Elevidys	Duchenne Muscular Dystrophy (DMD)	June 2023	10,000 to 15,000 prevalence; 8,200+ eligible	Ages 4 and older	\$3.2 million	
Roctavian®	Hemophilia A	June 2023	30,000 prevalence; 2,400 eligible	Ages 18 and older; no inhibitors	\$2.9 million	
Lyfgenia™ and Casgevy™			100,000 prevalence; 20,000 eligible	Ages 12 and older with severe SCD	\$3.1 million and \$2.2 million	

Fiscal Impact of Cell and Gene Therapies

- Member level data to support prevalence and eligible population estimates
- Member level drug utilization to support potential uptake estimates
- Provider relationships to understand member preferences
 and prescribing patterns
- Assessment of current policies that may limit access or otherwise affect current or future uptake rates
- Ability to engage in value-based purchasing (VBP) supplemental rebate agreements with manufacturers
- Ability to collect federal rebates for inpatient-administered CGTs
- Estimation of drug-specific cost offsets and/or ancillary costs

3 Risk Mitigation



High Level Overview of Risk Mitigation Considerations

Managed Care Philosophy



Advantages and Disadvantages


High-Cost Drug Risk Mitigation Options

	MCO Full Risk	Limited Carve-Outs	Risk Corridors	Kick Payments	Risk Pools	State Administered Reinsurance
Budget Predictability	+	-	—	-	+	+/_1
Incentive for MCOs to Manage Utilization	+	-	+	-	+	+
Incentive for MCOs to Manage Unit Cost	+	-	+	+	+	+
Directs Funds to MCOs with Highest Utilization	-	-	+	+	+	+
Maintains Integrated Managed Care Model	+	-	+	+	+	+
Requires Maintenance of a High-cost Drug List	—	+	+	+	+	-
VBP Operational Simplicity	—	+	_	-	-	-

¹ Dependent on the design of the reinsurance. Capped reinsurance is more predictable than open ended reinsurance arrangements funded by the State.


Administrative Complexity Continuum

Least Complex to Most Complex



Budget Predictability Continuum

Least Risk to the State to Most Risk to the State



Questions

David McMahon, CPA, Principal Financial and Operational Consultant David.McMahon@Mercer.com

Janine Statt, Pharm.D, Principal Pharmacy and Policy Consultant Janine.Statt@Mercer.com (805) 405-2699

Acknowledgements: Bethany Holderread, Payal Kotadiya







Erica Mitchell, FSA, MAAA

High-Cost Drugs

August 8, 2024

Agenda



Diabetes and Weight Loss Drugs

There is heavy focus on the GLP-1 drugs for weight loss and other possible indications. This presentation is an update and discussion of possible impact and future of this class of medicine.



CMS Sickle Cell Value-Based Payment (VBP) Model

CMS is launching a voluntary, value-based payment model for State Medicaid programs with CMS negotiating the deal terms through November 2024.





Diabetes and Weight Loss Drugs

GLP-1 Current State

Approval for Diabetes

Approval for Weight Loss

Approved for Cardiovascular Risk Reduction

Excluded from Medicare



Medicaid GLP-1 Utilization

U.S. Medicaid Utilization from KFF vs Single State Findings



Q3 Q4 01 Q2 Q3 Q4 Q1 Q2 Q3 Q4 01 Q2 Q3 Q4 01 Q2 Q3


Q1 Q2

2019

NOTE: GLP-1 = glucagon-like peptide-1. Gross spending is Medicaid spending before rebates. State Medicaid coverage of drugs approved for weight-loss (Wegovy in this analysis) is limited, but Ozempic, Rybelsus, and Mounjaro are approved to treat type 2 diabetes and covered by Medicaid KEFF in all states for that label indication.


SOURCE: KFF analysis of 2019-2022 State Drug Utilization Data, accessed August 2023. • PNG

Guidehouse



04 01

GLP-1 Future Studies



GLP-1 Drugs Show Promise in Alcohol, **Opioid Use Disorders**

Published: Aug 03, 2023 By Heather McKenzie

HEALTH

Fatty liver disease was alleviated by Lilly's 'triple-G' obesity drug in small study

By Elaine Chen y June 26, 2023 WEIGHT 🗐 NEWS

Could Blockbuster Weight Loss Drugs Also Be Used to Treat Heart Disease, Alzheimer's, and Cancer?

lobe are betting that GLP-1 medications like Ozempic, Mounjaro, and Wegovy may help treat a variety of medical condition

By Becky Upham 🤣 Fact Checked Published on January 5, 2024

HEALTH AND SCIENCE

Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says

PUBLISHED WED, AUG 16 2023-4:38 PM EDT



Novo Nordisk's Ozempic cuts mortality risk in kidney disease

May 24, 2024 7:06 AM ET | Novo Nordisk A/S (NVO) Stock | LLY, BAX, DVA ... | By: Dulan Lokuwithana, SA News Editor | 6 Comments

Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says

If the drug's approval is expanded to treat obstructive sleep apnea, insurers may be more likely to cover the pricy medication.

> 'Ozempic babies' are surprising women taking weight loss drugs. Doctors think they know why.



9 a.m. ET March 21, 2024 Updated 7:46 a.m. ET April 17, 2024

MEDICALNEWSTODAY

Can weight loss drugs actually

SHARE $\mathbf{f} \times \mathbf{i}$ help lower depression and anxiety risk?



New Potential Weight Loss Phase 3 Molecules

Company	Molecule/Product	Target	Administration Route
Boehringer Ingelheim	survodutide	GIP/GLP Glucagon receptor agonist	Subcutaneous (SC)
Eli Lilly	orforglipron	GIP/GLP Glucagon receptor agonist	Oral
Eli Lilly	mazdutide	GIP/GLP Glucagon receptor agonist	SC
Eli Lilly	retatrutide	GIP/GLP Glucagon receptor agonist	SC
Eurofarma Laboratorios	Sibutramine + Topiramate XR	Other	Oral
Novo Nordisk	Cagrilintide + semaglutide	Other	SC
Sciwind	ecnoglutide	GIP/GLP Glucagon receptor agonist	SC
Takeda	cetilistat	Gastric and pancreatic lipase inhibitor	Oral

Source: IQVIA, Fierce Biotech: A look at the R&D landscape in obesity, led by GLP-1s (fiercebiotech.com)

As new products enter the market, will prices of existing products abate?



Status of Data Protection and Global Patent Expiry for GLP-1 Receptor Agonist

Generic name	Brand name	Data protection expiry date	Pediatric extension	Data protection ended	Global Patent end date (US is later)	Patent expired
				(yes/no)	(for longest filed)	(yes/no)
	Ozempic	4-Jan-26	NA	No	20-Mar-26	No
Semaglutide	Rybelsus	4-Jan-26	NA	No	20-Mar-26	No
	Wegovy	4-Jan-26	NA	No	20-Mar-26	No
	Victoza	21-May-18	NA	Yes	18-Nov-24	No
Liraglutide	Saxenda	21-May-18	NA	Yes	18-Nov-24	No
Liraglutide–insulin degludec	Xultophy	21-May-18	NA	Yes	18-Nov-24	No
Dulaglutide	Trulicity	10-Nov-23	NA	No	25-Sep-39	No
Lixisenatide	Adlyxine	25-May-25	NA	No	26-Oct-32	No
Lixisenatide–insulin glargine	Soliqua	25-May-25	NA	No	26-Oct-32	No

GLP-1 = glucagon-like peptide-1

Source: NIH: https://www.ncbi.nlm.nih.gov/books/NBK602920/table/t03/

As global patents expire, TBD on how US pricing is impacted.



GLP-1 Financial Impact

Initial high costs

Potential savings on other treatments

- Sleep apnea
- Addiction
- Cardio events

Future savings as more products enter market – list and timeline of possible new entrants Future savings as patents expire and generics/ bioequivalents enter market – create patent expiry timeline(s)



GLP-1 Overall Impact to Payers

Pressure to cover these drugs will continue to increase

Pressure to find opportunities for potential savings on other covered products

Possible prior authorization or combine with other services to try to measure/ increase savings/payback

Increase interest in multi-state buying groups for Medicaid, etc.

Once generics emerge on market, incredible price/ prescription swings to any new generics



GLP-1 Opportunities for Payers

Increased need/ demand for data analytics

Increased need for "out of the box" data models to forecast possible impact across co-morbidity and multiple disease states

Data models might be leveraged as stand-alone tools to scrutinize potential patients to ensure cost/benefit

Al driven data models might emerge

Studies to focus on maintenance post weight-loss (e.g., behavior modification, lower dosages, tapering off medication, etc.)




Sickle Cell Disease

Sickle Cell Disease (SCD) Fast Facts^{1,2}

Medicaid has a high SCD prevalence, particularly concentrated in the South and in Black populations.

Prevalence is highly variable based on geography:



Sources:


1 https://www.medicaid.gov/medicaid/quality-of-care/downloads/sickle-cell-disease-infographic.pdf


2 https://www.nytimes.com/2024/05/06/health/sickle-cell-cure-first.html

Beneficiaries by Age and Sex

SCD Characteristics and Complications^{1,2}

Lifetime medical costs associated with sickle cell disease average \$1.7M.³





Beneficiaries with SCD Beneficiaries without SCD


High Burden of SCD on Patients and Families

- CDC 2017 data study indicates high emergency department, inpatient, and outpatient usage
- Patients can experience extreme pain which is unable to be controlled even by opioids
- Life span can be 20 years less than average American

Selected Diagnoses among Beneficiaries with SCD in 2017



Beneficiaries with SCD




Sources:

- 1 https://www.medicaid.gov/medicaid/guality-of-care/downloads/sickle-cell-disease-infographic.pdf
- 2 https://www.nytimes.com/2024/05/06/health/sickle-cell-cure-first.html
- 3 Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with
- commercial insurance | Blood Advances | American Society of Hematology (ashpublications.org)

SCD Impacts Beyond Healthcare¹

SCD results in \$1.5B in productivity and wage loss in the US annually, or \$15k/year in lost wages per person.¹



Sources:

<u>1 The true cost of sickle cell disease: \$1.5 billion in lost productivity per year - VCU News - Virginia Commonwealth University</u>



Cell and Gene Therapy Treatment Background

Treatments are expensive and there are current capacity limitations on the number of patients who can be served.




Costs

- \$1.7M: Avg lifetime medical costs associated with sickle cell (pre-gene therapy treatments)¹
- \$2.2M: Casgevy (Vertex) average cost per patient²
- \$3.1M: Lyfgenia (Bluebird) avg cost per patient²
- Additional considerations: weeks/months in hospital prior to delivery including chemo prior to stem cell implantation, fertility preservation coverage, travel expense coverage



- "Clinical trials included 30-35 people with sickle cell, aged 12 to 35, who were, on average, experiencing four severe pain episodes per year and just under three hospitalizations per year."
- Bluebird estimates it can only treat 85-105 patients per year, including sickle cell or beta thalassemia patients³
- One provider, Children's National, can accept only about 10 gene therapy patients a year.

Limited Treatment Center Locations²



Sources:


Guidehouse

<u>1 Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance | Blood Advances | American Society of Hematology (ashpublications.org)</u> 2 FDA approves world's first CRISPR-based medicine for sickle cell (statnews.com)

3 https://www.nytimes.com/2024/05/06/health/sickle-cell-cure-first.html

August 8, 2024

The patient's care journey is long and complex¹




Sources:

1 Cell and Gene Therapy (CGT) Access Model Overview for States (cms.gov) (slide 21)




CMS Cell and Gene Therapy (CGT) Access Model



CMS Cell and Gene Therapy (CGT) Access Model

Much is happening in 2024-2025.

- All states and U.S. territories that participate in the Medicaid Drug Rebate Program (MDRP) are eligible to apply to participate in the model. Participation is voluntary.
- States encouraged to submit non-binding letters of intent.
- States have to meet minimum requirements to participate.



Sources:

1 CGT Access Model Frequently Asked Questions | CMS

2 Cell and Gene Therapy (CGT) Access Model Overview for States (cms.gov) (slide 25)

Other Considerations

States should consider a number of additional items in evaluating this model, particularly for states with managed care coverage.

- Should a state consider carving these drugs out to fee-for-service to make the value-based payment easier to track and administer?
- If carved into managed care:
 - Should the state consider implementing high-cost drug risk corridors, risk pools, or stop loss per patient if these mitigation techniques don't currently exist?
 - How might retroactive recoupments fit into overall program risk corridors?
- Might a State use this as a test ground for pharmacy VBP?





Erica Mitchell Director, Healthcare Actuarial erica.mitchell@guidehouse.com (404) 771-5391

Grant Lindman Managing Consultant, State Health glindman@guidehouse.com 317-764-6577

Rachel Layman, ASA Managing Consultant, Healthcare Actuarial rlayman@guidehouse.com (240) 639-8136

Thank You

©2023 Guidehouse Inc. All rights reserved. Proprietary and competition sensitive. This content is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.

August 8, 2024

Guidehouse A outwit complexity™